Jan van de Winkel, Genmab CEO
June 28, 2023 07:06 AM EDT
R&D

Fresh off ap­proval, Ab­b­Vie and Gen­mab's CD3xCD20 bis­pe­cif­ic Ep­kin­ly scores in an­oth­er type of blood can­cer

Amber Tong

Just over a month af­ter land­ing their first ap­proval for ep­cori­ta­m­ab, now brand­ed as Ep­kin­ly, Gen­mab and Ab­b­Vie have a fresh slate of da­ta …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Bris­tol My­ers re­veals more job cuts in New Jer­sey

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

A service from the Financial Times